

## Publications

- 1 Jafari Y, **Yin M**, Lim C, Pople D, Evans S, Stimson J, Pham TM; LSHTM CMMID COVID-19 working group. Effectiveness of infection prevention and control interventions, excluding personal protective equipment, to prevent nosocomial transmission of SARS-CoV-2: a systematic review and call for action. *Infect Prev Pract*. 2021 Nov 29:100192. doi: 10.1016/j.infpip.2021.100192. Epub ahead of print. PMID: 34870142; PMCID: PMC8628369.
- 2 **Mo Y**, Eyre DW, Lumley SF, Walker TM, Shaw RH, O'Donnell D, Butcher L, Jeffery K, Donnelly CA; Oxford COVID infection review team, Cooper BS. Transmission of community- and hospital-acquired SARS-CoV-2 in hospital settings in the UK: A cohort study. *PLoS Med*. 2021 Oct 12;18(10):e1003816. doi: 10.1371/journal.pmed.1003816. PMID: 34637439.
- 3 **Mo Y**, West TE, MacLaren G, *et al*. Reducing antibiotic treatment duration for ventilator-associated pneumonia (REGARD-VAP): a trial protocol for a randomised clinical trial. *BMJ Open* 2021;11:e050105. doi: 10.1136/bmjopen-2021-050105
- 4 Lim C, **Mo Y**, Teparrukkul P, Hongsuwan M, Day NPJ, Limmathurotsakul D, Cooper BS. Effect of Delays in Concordant Antibiotic Treatment on Mortality in Patients with Hospital-Acquired Acinetobacter spp. Bacteremia: Emulating a Target Randomised Trial with a 13-year Retrospective Cohort. *Am J Epidemiol*. 2021 May 27:kwab158. doi: 10.1093/aje/kwab158. Epub ahead of print. PMID: 34048554.
- 5 Kalisvar Marimuthu, **Yin Mo**, Moi Lin Ling *et al*. Household transmission of carbapenemase-producing Enterobacteriaceae (CaPES-C): A prospective cohort study. *J Antimicrob Chemother*. 2021 Apr 13;76(5):1299-1302.
- 6 A Henderson, D L Paterson, M D Chatfield, P A Tambyah, D C Lye, P P De, R T P Lin, K L Chew, **M Yin**, MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN). Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study. *Clin Infect Dis*. 2020 Oct 27:ciaa1479. doi: 10.1093/cid/ciaa1479. Epub ahead of print. PMID: 33106863.  
**Mo Y**, Hernandez-Koutoucheva A, Musicha P, Bertrand D, Lye D, Ng O, *et al*. Duration of Carbapenemase-Producing Enterobacteriaceae Carriage in Hospital Patients. *Emerg Infect Dis*. 2020;26(9):2182-2185. <https://dx.doi.org/10.3201/eid2609.190592>
- 7 Ong SC, Yap JX, Tay TYF, **Mo Y**, Loon SC, Koh V. Considerations in the use of slit lamp shields to reduce the risk of respiratory virus transmission in coronavirus disease 2019. *Curr Opin Ophthalmol*. 2020;31(5):374-379. doi:10.1097/ICU.0000000000000690
- 8 **Yin Mo**, Cherry Lim, James A Watson, Nicholas J White, Ben S Cooper. Non-adherence in non-inferiority trials: pitfalls and recommendations. *BMJ*. 2020;370:m2692. Published 2020 Jul 10. doi:10.1136/bmj.m2692
- 9 **Yin M**, Tambyah PA, Perencevich EN. Infection, Antibiotics, and Patient Outcomes in the Intensive Care Unit. *JAMA*. 2020;10.1001/jama.2020.2241. doi:10.1001/jama.2020.2241
- 10 **Yin Mo**, Cherry Lim, Mavuto Mukaka, Ben Cooper. Statistical considerations in the design and analysis of non-inferiority trials with binary endpoints in the presence of non-adherence: a simulation study. *Wellcome Open Res*. 2020;4:207. Published 2020 Apr 24. doi:10.12688/wellcomeopenres.15636.2
- 11
- 12 **Mo Y**, Lee CK, Loh TP, Koay ESC, Tang JW, Lee CC. Next generation sequencing identifies multi-drug resistant herpes simplex virus- associated scrotal ulceration. *J Infect*. 2019 Oct 18. pii: S0163-4453(19)30321-4. doi: 10.1016/j.jinf.2019.10.011.
- 13 Pouwels KB, **Yin M**, Butler CC, Cooper BS, Wordsworth S, Walker AS, Robotham JV. Optimising trial designs to identify appropriate antibiotic treatment durations. *BMC Med*. 2019 Jun 21;17(1):115. doi: 10.1186/s12916-019-1348-z.
- 14 Rene Niehus, Esther Van Kleef, **Yin Mo**, Agata Turlej-Rogacka, Christine Lammens, Yehuda Carmeli, Herman Goossens, Evelina Tacconelli, Biljana Carevic, Surbhi Malhotra-Kumar, Ben S Cooper. Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance. *Elife*. 2020;9:e49206. Published 2020 May 7. doi:10.7554/eLife.49206

- 15 **Mo Y**, Seah I, Lye PSP, et al Relating knowledge, attitude and practice of antibiotic use to extended-spectrum beta-lactamase-producing Enterobacteriaceae carriage: results of a cross-sectional community survey. *BMJ Open* 2019;9:e023859. doi: 10.1136/bmjopen-2018-023859
- 16 Oonsivilai M, **Mo Y**, Luangasanatip N et al. Using machine learning to guide targeted and locally-tailored empiric antibiotic prescribing in a children's hospital in Cambodia. *Wellcome Open Res* 2018, 3:131
- 17 Harris PNA, Tambyah PA, Lye DC, **Mo Y**; MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN). Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. *JAMA*. 2018 Sep 11;320(10):984-994.
- 18 **Y. Mo**, I. Low, S.K. Tambyah, P.A. Tambyah. The socio-economic impact of multidrug-resistant nosocomial infections: a qualitative study. *Journal of Hospital Infection*. 2018 Aug 29. pii: S0195-6701(18)30446-8.
- 19 Ng QX, Loke W, Foo NX, **Mo Y**, Yeo WS, Soh AYS. A systematic review of the use of rifaximin for Clostridium difficile infections. *Anaerobe*. 2018 Nov 2;55:35-39.
- 20 Ng QX, Venkatanarayanan N, De Deyn MLZQ, Ho CYX, **Mo Y**, Yeo W-S. A meta-analysis of the association between Helicobacter pylori (H. pylori) infection and hyperemesis gravidarum. *Helicobacter*. 2018;23:e12455.
- 21 Patrick Harris, Nouri Ben Zakour, Leah W. Roberts, Alex M. Wailan, Hosam M. Zowawi, Paul A. Tambyah, David C. Lye, Roland Jureen, Tau H. Lee, Ezlyn Izharuddin, **Mo Yin**, David Looke, Naomi Runnegar, Benjamin Rogers, Hasan Bhally, Amy Crowe, Mark A. Schembri, Scott Beatson, David L. Paterson. Dominance of ST131. Escherichia coli carrying blaCTX-M in patients with bloodstream infections caused by cephalosporin-resistant strains in Australia, New Zealand and Singapore: whole genome analysis of isolates from a randomised trial. *J Antimicrob Chemother*. 2017 Dec 14. doi: 10.1093/jac/dkx466.
- 22 **Y Mo**, Fisher DA. A review of treatment modalities for Middle East Respiratory Syndrome. *J Antimicrob Chemother* 2016 Dec; 71(12): 3340-3350. Epub 2016 Sep 1.
- 23 **Y Mo**, B Salada, PA Tambyah. Zika virus—a review for clinicians. *Br Med Bull* 2016; 119 (1): 25-36.
- 24 **Y Mo**, Archuleta S, Salmon S, Fisher D. Residency Training at the Front of the West African Ebola Outbreak: Adapting for a Rare Opportunity. *PLOS Currents Outbreaks* 2016 Feb 2. Edition 1.
- 25 **Y Mo**, PA Tambyah. The 2009 influenza pandemic and Ebola crisis: What are the lessons learnt? *Future Virology* 2015; 10: 335-9.
- 26 P Harris, **Y Mo**, R Jureen, J Chew, D Paterson, PA Tambyah. Comparable outcomes for  $\beta$ -lactam/ $\beta$ -lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant *Escherichia coli* or *Klebsiella pneumoniae*. *Antimicrob Resist Infect Control* 2015; 4: 14.
- 27 Harris PN, AD Wang, **Y Mo**, CK Lee, S Archuleta. Atypical hand, foot, and mouth disease: eczema coxsackium can also occur in adults. *Lancet Infect Dis* 2014; 14: 1043.